| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
The specific molecular target of Sagittatoside A is not fully characterized. As a flavonoid glycoside and triterpenoid saponin, it may interact with multiple cellular targets including inflammatory mediators, viral proteins, and signaling molecules. The compound exhibits anti-inflammatory activity, likely through modulation of inflammatory signaling pathways such as NF-κB and MAPK. Its anti-viral properties suggest it may interfere with viral entry, replication, or assembly.
|
|---|---|
| ln Vitro |
Sagittatoside A is a natural flavonoid glycoside with anti-inflammatory and anti-viral properties. It is found in Epimedium species (Yinyanghuo) and is also extracted from Lonicera japonica Thunb. The compound belongs to the triterpenoid saponin family and is also known as Icariin A. It exhibits anti-inflammatory effects, likely through modulation of inflammatory mediators and signaling pathways. The compound also shows anti-viral activity, suggesting potential applications in viral infections. Its molecular weight is 676.66 with the formula C33H40O15.
|
| ln Vivo |
No specific in vivo activity data are documented for Sagittatoside A. As a natural product with anti-inflammatory and anti-viral properties, it has potential for in vivo efficacy in models of inflammation and viral infections. The compound's natural origin and use in traditional medicine suggest it may be well-tolerated. Further in vivo studies including pharmacokinetics and efficacy in animal models of inflammation or viral disease would be valuable for therapeutic development.
|
| Enzyme Assay |
In vitro enzyme assays for Sagittatoside A may include evaluation of anti-inflammatory activity through COX-2 or LOX inhibition assays. The compound is incubated with the enzyme of interest in appropriate buffer systems, and enzyme activity is measured using chromogenic or fluorogenic substrates. For anti-viral activity, viral protease or polymerase inhibition assays can be performed. The compound may also be evaluated for its ability to inhibit inflammatory cytokine production in stimulated immune cells. Standard protocols involve incubating the compound with the enzyme or cells and measuring the relevant activity or product formation.
|
| Cell Assay |
Cell-based assays for Sagittatoside A include evaluation of anti-inflammatory and anti-viral effects. For anti-inflammatory activity, macrophage cell lines (e.g., RAW 264.7) are treated with varying concentrations of Sagittatoside A (1-100 μM) prior to LPS stimulation. Inflammatory markers such as NO, TNF-α, IL-6, and IL-1β are measured. For anti-viral activity, virus-infected cells (e.g., influenza virus in MDCK cells) are treated with the compound, and viral replication is measured by plaque assay, qPCR, or cytopathic effect (CPE) reduction. Cytotoxicity is assessed using MTT or CCK-8 assays.
|
| Animal Protocol |
No specific in vivo animal models are documented for Sagittatoside A. For potential in vivo studies, the compound could be administered orally or intraperitoneally to rodents in models of inflammation (e.g., carrageenan-induced paw edema, LPS-induced sepsis) or viral infection (e.g., influenza virus challenge). Doses would be selected based on preliminary pharmacokinetic and tolerability assessments. Endpoints may include inflammatory cytokine levels, viral titers, tissue histology, and survival rates. The compound's natural origin suggests it may be suitable for oral administration.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data are available for Sagittatoside A. As a flavonoid glycoside with a molecular weight of 676.66, the compound is relatively large and hydrophilic, which may limit oral bioavailability. Flavonoid glycosides are typically metabolized by gut microbiota to release the aglycone, which may be absorbed. The compound should be stored at 2-8°C for up to 24 months when kept tightly sealed. Solubility in aqueous and organic solvents should be determined experimentally. Further PK studies would be necessary for in vivo applications.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are documented for Sagittatoside A. As a natural compound isolated from a traditional Chinese herb, it is expected to have low toxicity based on traditional use. However, systematic toxicity studies including acute toxicity, subchronic toxicity, genotoxicity, and organ-specific toxicity would be required for therapeutic development. The compound is intended for research use only and is not approved for human therapeutic applications. Standard laboratory safety practices should be followed when handling the compound.
|
| Additional Infomation |
Sagittatoside A is a glycoside belonging to the flavonoid class of compounds. It has been reported to be found in Epimedium sagittatum, Epimedium diphyllum, and Epimedium grandiflorum, and relevant data are available for reference.
Sagittatoside A has the IUPAC name 3-[(6-deoxy-2-O-β-D-glucopyranosyl-α-L-mannopyranosyl)oxy]-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyran-4-one. It has a purity of ≥98%. The compound is a flavonoid glycoside with a sugar moiety consisting of a deoxy-mannose (rhamnose) with a glucose substitution. It is isolated from Herba Epimedii, a plant used in traditional Chinese medicine. The compound is also known as Icariin A. It is for research use only. |
| Molecular Formula |
C33H40O15
|
|---|---|
| Molecular Weight |
676.6617
|
| Exact Mass |
676.236
|
| CAS # |
118525-35-2
|
| Related CAS # |
Iso-Sagittatoside A;503456-08-4
|
| PubChem CID |
13916054
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.6±0.0 g/cm3
|
| Boiling Point |
933.3±0.0 °C at 760 mmHg
|
| Flash Point |
295.8±0.0 °C
|
| Vapour Pressure |
0.0±0.0 mmHg at 25°C
|
| Index of Refraction |
1.679
|
| LogP |
2.71
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
48
|
| Complexity |
1170
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=C(C(=CC(=C3C2=O)O)O)CC=C(C)C)C4=CC=C(C=C4)OC)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O
|
| InChi Key |
COHHGQPQHHUMDG-WVQJJEIESA-N
|
| InChi Code |
InChI=1S/C33H40O15/c1-13(2)5-10-17-18(35)11-19(36)21-24(39)30(28(46-29(17)21)15-6-8-16(43-4)9-7-15)47-33-31(26(41)22(37)14(3)44-33)48-32-27(42)25(40)23(38)20(12-34)45-32/h5-9,11,14,20,22-23,25-27,31-38,40-42H,10,12H2,1-4H3/t14-,20+,22-,23+,25-,26+,27+,31+,32-,33-/m0/s1
|
| Chemical Name |
3-[(2S,3R,4R,5R,6S)-4,5-dihydroxy-6-methyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~31.25 mg/mL (~46.18 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.07 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.07 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4778 mL | 7.3892 mL | 14.7785 mL | |
| 5 mM | 0.2956 mL | 1.4778 mL | 2.9557 mL | |
| 10 mM | 0.1478 mL | 0.7389 mL | 1.4778 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
